Professor Rob Sutherland FAA AO
Senior Principal Research Fellow; Director, Cancer Research Program, Garvan Institute of Medical Research; NHMRC Senior Principal Research Fellow; Conjoint Professor, Faculty of Medicine, The University of New South Wales
Email: r.sutherland 'at' garvan.org.au
Research Group: Prostate Cancer, Steroid Hormone Action, Breast Cancer
Education
B AgrSc, University of Canterbury, New Zealand
M AgrSc, University of Canterbury, New Zealand
PhD, Australian National University, Canberra
Awards and Honours
1994 DSc (Honoris causa) Lincoln University, New Zealand
2000 The Ramaciotti Medal for Excellence in Biomedical Research
2002 Fellow of the Australian Academy of Science
2003 Centenary of Federation Medal for service to Australian society and science in molecular and cellular biology
2010 Officer, General Division of the Order of Australia
Publications
Millar EKA, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C and Sutherland RL. Prediction of local recurrence, distant metastases and death following breast-conserving therapy in early-stage invasive breast cancer using a five biomarker panel. J Clin Oncol: 2009; In Press.
Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, Nguyen NQ, Leong RWL, Cosman PH, Kelly MI, Sutherland RL, Henshall SM, Kench JG and Biankin AV. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol: 2009; 10.1200 / JCO.2008.20.5104.
Millar EKA, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CES, Witkiewicz A, Musgrove EA, Rui H, LeMarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL and Knudsen ES. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene:2009; 28: 1812-1820.
Biankin AV, Kench JG, Colvin EK, Davendra S, Scarlett CJ, Ngyuen NQ, Chang DK, Morey A, Lee C-S, Pinese M, Kuo SC, Susanto J, Cosman PH, Lindeman G, Visvader J, Nguyen TV, Merrett ND, Warusavitarne J, Musgrove EA, Henshall SM and Sutherland RL. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009; 10.1053 / j.gastro.2009; 04.009.
Alles CM, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA and Ormandy CJ . Meta-analysis and gene set enrichment relative to ER status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One:2009; 4: e4710.
Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles CM, Pinese M, Caldon CE, Schutte J, Gardiner-Garden M, Ormandy CJ, McArthur G, Butt AJ and Sutherland RL. Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One:2008; 3: e2987.
Caldon CE, Swarbrick A, Lee CS, Sutherland RL and Musgrove EA. The HLH protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res:2008; 68: 3026-3036.
Caldon CE, Lee CS, Sutherland RL and Musgrove EA. Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation. Oncogene:2008; 27: 126-138.
Butt AJ, Sergio CM, Inman CK, Anderson LR, McNeil CM, Russell AJ, Nousch M, Preiss T, Biankin AV, Sutherland RL and Musgrove EA. The estrogen and c-Myc target gene, HSPC111, is overexpressed in breast cancer and associated with poor patient outcome. Breast Cancer Res :2008; 10: R28.
Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG and Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98: 1420-1424
